跳至主要内容
临床试验/NCT01943097
NCT01943097Unknown不适用

The Evaluation of the 6-[18F]Fluoro-levo-dopa and 123I-MIBG Uptake in the Patients With Neuroblastoma

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 160 人开始时间: 2007年6月最近更新:
适应症

试验速览

阶段
不适用
入组人数
160
试验地点
1
主要终点
The maximum standardized uptake value and tumor-to-liver uptake ratio

研究概览

简要总结

Neuroblastic tumors are childhood neoplasms that possess amino acid decarboxylase (AADC) activity and Meta-iodobenzylguanidine(MIBG), they can theoretically be imaged by (18)F-fluorodihydroxyphenylalanine ((18)F-FDOPA) and (123)I-Meta-iodobenzylguanidine((123)I-MIBG) PET, they are new and specific diagnostic and follow-up tools for neuroendocrine tumors. In this study, we explored the accuracy and clinical role of (18)F-FDOPA and (123)I-MIBG PET in neuroblastic tumors.

METHODS:

Patients with tissue-proven neuroblastic tumors receiving (18)F-FDOPA PET or (123)I-MIBG at initial diagnosis or during follow-ups were enrolled. The sensitivity and specificity of (18)F-FDOPA or (123)I-MIBG PET were compared to each other and compared to(18)F-FDG PET, using tumor histology as the standard.

研究设计

研究类型
Observational
观察模型
Case Crossover
时间视角
Cross Sectional

入排标准

年龄范围
— 至 30 Years(Child, Adult)
性别
All
接受健康志愿者

入选标准

  • (1) Diagnosed by clinical criteria(one of below)
  • Proved as Neuroblastoma by a pathological section
  • Bone meta with 24 hrs urine VMA(Vanillylmandelic acid )or HVA (Homovanillic acid) elevated
  • CT or MRI found tumor around adrenal gland or Neuroblastic tumor
  • (2) Age between 0-30 years old,Body weight over 2.5kg
  • (3) Signed Inform Consent Form

排除标准

  • (1)AST and ALT > 200U/L、Cre > 2.5mg/dl
  • (2)Allerg to 18F-dopa、123I-MIBG
  • (3)Subject not fit this study(assessed by PI)
  • (4)No more need to arrenge PET because disease progress, assessed by VS

结局指标

主要结局

The maximum standardized uptake value and tumor-to-liver uptake ratio

时间窗: Outcome will be measured in one week after performed.

The maximum standardized uptake value and tumor-to-liver uptake ratio will be evaluated by specific Nuclear Medicine doctor.

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验